SpringerLink
Log in

Sunitinib—a new standard of care for metastatic renal cell carcinoma

  • Practice Point
  • Published:

From Nature Clinical Practice Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Motzer RJ et al. (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530–2540

    Article  CAS  Google Scholar 

  2. Coppin C et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Systematic Reviews 2000, Issue 3 Art. No.: CD001425 DOI: 10.1002/14651858.CD001425.pub2

  3. Escudier B et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125–134

    Article  CAS  Google Scholar 

  4. Yang JC et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434

    Article  CAS  Google Scholar 

  5. Hudes G et al. (2006) A phase 3, randomized, 3-arm study of temsirolimus or interferon-alpha or the combination in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. [abstract]. J Clin Oncol 24: LBA4

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. WM Stadler is a Professor of Medicine and Surgery in the sections of Hematology/Oncology and Urology, and RZ Szmulewitz is a Hematology/Oncology Fellow, both at the University of Chicago, Chicago, IL, USA.,

    Walter M Stadler & Russell Z Szmulewitz

Authors
  1. Walter M Stadler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Russell Z Szmulewitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Walter M Stadler.

Ethics declarations

Competing interests

WM Stadler has received research funding from Amgen, AstraZeneca, Bayer, Genentech, Novartis, Pfizer and Wyeth, and consulting fees from Amgen, AstraZeneca, Bayer, Novartis and Onyx.

RZ Szmulewitz declared he has no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stadler, W., Szmulewitz, R. Sunitinib—a new standard of care for metastatic renal cell carcinoma. Nat Rev Clin Oncol 4, 458–459 (2007). https://doi.org/10.1038/ncponc0882

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0882

  • Springer Nature Limited

Search

Navigation